Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance

Annals of Oncology

Volumn 14, Issue 4, 2003, Pages 643-647

  Etienne, M C ^a   Leger, F ^b   Pivot, X ^a   Chatelut, E ^b   Bensadoun, R J ^a   Guardiola, E ^a   Renee N ^a   Magne N ^a   Canal, P ^b   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Carboplatin disposition; Chatelut formula; Head and neck cancer; Low dose carboplatin; Pharmacokinetic; Radiotherapy

Indexed keywords

CARBOPLATIN; CREATININE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BAYES THEOREM; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; FILTRATION; HEAD AND NECK TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; THEORETICAL MODEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BAYES THEOREM; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FILTRATION; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS;

EID: 0037481742     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg162     Document Type: Article

References (25)

1. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 4: 520-528.
2. Egorin MJ, Van Echo DA, Tipping SJ et al. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedi-carboxylato) platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432-5438.
3. Du Full SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997; 33: 161-183.
4. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
5. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-580.
6. Huw T, Boddy AV, English MW et al. Prospective validation of renal function-based carboplatin dosing in children with cancer: a United Kingdom children's cancer study group trial. J Clin Oncol 2000; 18: 3614-3621.
7. Ghazal-Aswad S, Tilby MJ, Lind M et al. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels. Ann Oncol 1999; 10: 329-334.
8. Mazumbar M, Smith A, Tong WP, Motzer RJ. Calvert's formula for dosing carboplatin: overview and concerns of applicability in high-dose setting. J Natl Cancer Inst 2000; 92: 1434-1436.
9. Forastiere AA. Cisplatin and radiotherapy in the management of locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1993; 27: 465-470.
10. Glaser MG, Leslie MD, O'Reilly SM et al. Weekly cisplatinum concomitant with radical radiotherapy in the treatment of advanced head and neck cancer. Clin Oncol 1993; 5: 286-289.
11. Al-Sarraf M. Cisplatin combinations in the treatment of head and neck cancer. J Clin Oncol 1994; 21: 28-34.
12. Zamboglou N, Schnabel T, Kolotas C et al. Carboplatin and radiotherapy in the treatment of head and neck cancer: six year's experience. Semin Oncol 1994; 21: 45-53.
13. Jeremic B, Shibamoto Y, Stanisavljevic B et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997; 43: 29-37.
14. Bensadoun RJ, Etienne MC, Dassonville O et al. Concomitant B.I.D. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. Int J Radiat Oncol Biol Phys 1998; 42: 237-245.
15. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14: 838-847.
16. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949-955.
17. Grigsby PW. Cervical cancer: combined modality therapy. Cancer J 2001; 7: 47-50.
18. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Chatelut E, Pivot X, Otto J et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000; 36: 264-269.
20. Peng B, Boddy AV, Cole M et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer 1995; 31: 1804-1810.
21. Huitema ADR, Mathôt RAA, Tibben MM et al. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 2000; 67: 621-630.
22. Murry DJ, Sandlund JT, Stricklin LM, Rodman JH. Pharmacokinetics and acute renal effects of continuously infused carboplatin. Clin Pharmacol Ther 1993; 54: 374-380.
23. Tonda ME, Heideman RL, Petros WP et al. Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemother Pharmacol 1996; 38: 395-400.
24. Sculier JP, Paesmans M, Thiriaux J et al. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. Eur J Cancer 1999; 35: 1314-1319.
25. Schwartz GN, Pendyala L, Kindler H et al. The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer 1998; 34: 1543-1548.